The global allergen diagnostic market will reach $3.8 billion by 2024

Allergen diagnosis refers to the rapid, accurate and painless detection of allergens by enzyme immunology. Allergen diagnosis remains an important business in the biological industry, with allergen diagnostics expected to triple from $1.3 billion in 2015 to $3.8 billion in 2024, according to a recent report by Transparity Market Research, a leading industry research firm.
allergens include food allergens, inhaled allergens, and other allergens in the global allergy diagnostic market. The main products include diagnostic reagents, diagnostic supplies and diagnostic equipment. Subdivision instruments include immunoanalysts, spectrographs, etc. Key end users include academic research institutions, diagnostic laboratories, hospitals, and other users such as CRO and pharmaceutical companies.
major manufacturers in the
Allergy Diagnostics market include BioMerieux (France), Danaher Group (USA), Foundel Chemical Diagnostics (USA), HOB Biotech Group (China), Hycor Biomedical (USA), Lincoln Diagnostics (USA), Omega Diagnostics (UK), Siemens Medical (Germany), Stallergenes (France) and Thermo Fisher (USA).1, five giants control 73% of the market
report also notes that five companies control 73% of the global market in the allergen diagnostics segment, followed by Thermo Fisher Scientific, Quest Diagnostics., BioMerieux, Omega Diagnostics and France's Stagenes.
10 laboratories around the world use the company's technology, according to the company's website. But analysts say it remains to be seen whether Seymru will retain its position as one of the five allergen diagnostic giants, but there is no doubt that the company's business has great potential for growth as global allergen diagnosis rates rise.2, the growth potential of developed countries is not reduced
in addition to providing rich economic benefits for allergen diagnostic companies, developed countries have also been disproportionately affected. Citing global asthma burden statistics from 2013, the report found that allergy rates in the UNITED States, the United Kingdom, Australia and New Zealand were 20 times higher than in other countries.
, the report predicts that the North American market will account for about 40 per cent of the global market, although it also notes that future expansion of the Asia-Pacific market will also show an alarming compound annual growth rate for the expansion of the Asia-Pacific market.
interview, an allergen expert described how humans react to allergens. Steve Wilson, chief operating officer of the La Jolla Institute for Allergy and Immunology, explains that allergic reactions are overreactions by the immune system to things that are not inherently dangerous. As a result of the great improvement of the public health environment in modern society, human beings are exposed to much fewer microorganisms than we were when we evolved. Everything that removes beneficial microbes and overreacts the immune system is allergens.
However, experts say the so-called "health hypothesis" is only one of the risk factors allergy researchers are investigating, as well as overuse of antibiotics and the neglect of common allergens by healthy people, which in turn increases their risk.
report, patients and suppliers may have a change in their perceptions of allergy testing by 2024. However, the change does not come from Theranos, known as "a drop of blood", and many other companies are redesigning the allergy testing process. Austrian start-up Kiweno's allergy test, for example, provides consumers with a 23andme-style sample collection tool that allows users to collect samples at home and access their results through an online platform, as well as personalized dietary advice and community academic support.3, accompanying diagnosis is another diagnostic "big cake
it's worth noting that in addition to allergen diagnosis, the study notes that accompanying diagnosis can be another lucrative area, especially in the asthma business.
2015, AstraZeneta announced an agreement with Abbott to establish an accompanying diagnosis of its asthma antibody drug, tralokinumab. It is reported that at present in the field of asthma treatment has not been approved accompanying diagnosis, and now the cooperation between the two sides is still in phase III clinical trials. (Biological Exploration)